ProQR Therapeutics N.V.
PRQR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $18,905 | $6,514 | $3,594 | $1,335 |
| % Growth | 190.2% | 81.2% | 169.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $18,905 | $6,514 | $3,594 | $1,335 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $36,356 | $25,148 | $50,867 | $42,220 |
| G&A Expenses | $13,661 | $16,236 | $18,651 | $17,368 |
| SG&A Expenses | $13,661 | $16,236 | $18,651 | $17,368 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$640 | -$3,011 | -$765 | -$1,043 |
| Operating Expenses | $49,377 | $38,373 | $68,753 | $58,545 |
| Operating Income | -$30,472 | -$31,859 | -$65,159 | -$57,210 |
| % Margin | -161.2% | -489.1% | -1,813% | -4,285.4% |
| Other Income/Exp. Net | $2,512 | $4,046 | $1,051 | -$3,472 |
| Pre-Tax Income | -$27,960 | -$27,813 | -$64,108 | -$60,682 |
| Tax Expense | -$197 | -$78 | $96 | $117 |
| Net Income | -$27,763 | -$28,119 | -$64,424 | -$60,740 |
| % Margin | -146.9% | -431.7% | -1,792.5% | -4,549.8% |
| EPS | -0.34 | -0.35 | -0.91 | -0.96 |
| % Growth | 2.9% | 61.5% | 5.2% | – |
| EPS Diluted | -0.34 | -0.35 | -0.91 | -0.96 |
| Weighted Avg Shares Out | 81,666 | 81,011 | 71,641 | 64,182 |
| Weighted Avg Shares Out Dil | 81,666 | 81,011 | 71,641 | 64,182 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,251 | $2,593 | $106 | $5 |
| Interest Expense | $1,077 | $1,203 | $5,127 | $3,405 |
| Depreciation & Amortization | $2,761 | $2,513 | $2,521 | $2,329 |
| EBITDA | -$24,122 | -$24,097 | -$56,460 | -$54,948 |
| % Margin | -127.6% | -369.9% | -1,571% | -4,116% |